In our study, three categories of side effects were reported from both anti-PD1 and anti-PD-L1 agents, namely, musculoskeletal (overall 39.5%; 38.3% for fatigue and 4.4% for arthralgia), gastrointestinal (overall 35.7%; 29.9% for nausea and vomiting and 12.4% for diarrhea), and dermatological (7.5% pruritis, itchiness, and eczema) side effects. Here, CD274 is linked to Eczematoid dermatitis.